Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

NCT05482516 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT05482516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05482516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease
Lead sponsor
Georgetown University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 29, 2023
Completion date
December 31, 2027
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of biliary tract, colon adenocarcinoma, gallbladder adenocarcinoma, gastric adenocarcinoma, hepatocellular carcinoma, pancreatic adenocarcinoma, rectal adenocarcinoma